Star Therapeutics

Executive Summary

Star Therapeutics is a late clinical-stage biotechnology company focused on discovering and developing best-in-class antibody therapies for serious diseases, with a novel 'pipeline-in-a-product' strategy. Its lead program, VGA039, is a first-in-class monoclonal antibody targeting Protein S for the treatment of bleeding disorders, initially addressing von Willebrand disease (VWD), the most common inherited bleeding disorder. VGA039 has the potential to provide a universal hemostatic agent that could improve upon current therapies limited by short half-life, immunogenicity, and restricted efficacy across subtypes. The company is headquartered in South San Francisco, California, and was founded in 2018. While Star operates as a private entity and has not disclosed total funding or valuation, its focus on a large unmet medical need and a differentiated mechanism positions it as a potential leader in hemostasis innovation. Key upcoming catalysts include Phase 1/2 clinical data for VGA039 in VWD, which could de-risk the platform and support expansion into other bleeding indications such as hemophilia or platelet disorders. The company's pipeline-in-a-product approach also suggests future opportunities in additional disease areas beyond hemostasis.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 Clinical Data for VGA039 in von Willebrand Disease60% success
• H1 2027Initiation of a Second Indication Trial (e.g., Hemophilia A or B)40% success
• H2 2026Potential Partnership or Licensing Deal for VGA03950% success